Clinical Trial Search

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Overall Survival — 24.8 Months

Primary: Median Overall Survival (OS) — 42 months

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Survival — 37; 31 participants

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Overall Survival at 18 Months — 63 percentage of participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Conversion Rate of Inoperable to Operable

Primary: Progression Free Survival Rate — 67 percentage of participants

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.

Primary: Tarceva Maximum Tolerated Dose in mg — 150 mg

Primary: Surgical Exploration — 4; 6; 9 Participants

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Overall Survival at 2 Years — 0.54 proportion of patients

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants